Erratum: Pharmacogenetics of drug hypersensitivity in the 2010 issue of Pharmacogenomics (Pharmacogenomics (2010) 11:7 (973–987) DOI: 10.2217/pgs.10.77);Pharmacogenetics of drug hypersensitivity

Pharmacogenomics

Volumn 11, Issue 7, 2010, Pages 973-987

  Phillips, Elizabeth J ^a,b,c,d   Mallal, Simon A ^a,b,c,d  

^a ROYAL PERTH HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c Centre for Clinical Pharmacology and Infectious Diseases   (Australia)

^d MURDOCH UNIVERSITY   (Australia)

Author keywords

HIV; human leukocyte antigen; hypersensitivity; pharmacogenetics; pharmacogenomics; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AUROTHIOMALATE; CARBAMAZEPINE; CLOZAPINE; DARUNAVIR PLUS RITONAVIR; DICLOFENAC; EFAVIRENZ; FEPRAZONE; FLUCLOXACILLIN; HYDRALAZINE; ISONIAZID; LAMIVUDINE; LAMOTRIGINE; LEVAMISOLE; METHYLDOPA; NEVIRAPINE; OXICAM DERIVATIVE; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; QUINIDINE; SULFAMETHOXAZOLE; SULFONAMIDE; UNINDEXED DRUG; XIMELAGATRAN;

AGRANULOCYTOSIS; ANGIONEUROTIC EDEMA; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CROSS REACTION; DRESS SYNDROME; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; EOSINOPHILIA; ETHNIC DIFFERENCE; FALSE POSITIVE RESULT; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC SCREENING; GOUT; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; HYPOTENSION; LEUKOPENIA; LUPUS LIKE SYNDROME; MYASTHENIA GRAVIS; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTIVE VALUE; PREVALENCE; PROTEINURIA; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SKIN TEST; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; URTICARIA; VIRUS REACTIVATION;

EID: 77954365622     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.77e1     Document Type: Erratum

References (109)

1. Gomes ER, Demoly P: Epidemiology of hypersensitivity drug reactions. Curr. Opin. Allergy Clin. Immunol. 5, 309-316 (2005).
2. Edwards JR, Aronson JK: Adverse drug reactions: defnitions, diagnosis and management. Lancet 356, 1255-1259 (2000).
3. Hung SI, Chung WH, Liou LB et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse drug reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134-4139 (2005).
4. Tassaneevakul W, Jantararoungtong T, Chen P et al.: Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19, 704-709 (2009).
5. Chung WH, Hung SI, Hong HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
6. Man CB, Kwan P, Baum KL et al.: Association between HLA-B*1502 and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48, 1015-1018 (2007).
7. Locharenkul C, Loplumlert J, Limotai C et al.: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49, 2087-2091 (2008).
8. Lonjou C, Borot N, Sekula P et al.: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to fve high-risk drugs. Pharmacogenet. Genomics 18, 99-107 (2008).
9. Roujeau JC, Huynh TN, Bracq C et al.: Genetic susceptibility to toxic epidermal necrolysis. Arch. Dermatol. 123, 1171-1173 (1987).
10. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
11. Hetherington S, Hughes AR, Mosteller M et al.: Genetic variation in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
12. Martin AM, Nolan D, James I et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T cell count. AIDS 19, 97-99 (2005).
13. Littera R, Carcassi C, Masala A et al.: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20, 1621-1626 (2006).
14. Gatanaga H, Yazaki H, Tanuma J et al.: HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21, 264-265 (2007).
15. Chantarangsu S, Mushiroda T, Maharasirimongkol S et al.: HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 9, 139-146 (2009).
16. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 7, 297-306 (2006).
17. Afrevic A, Jorgensen AL, Williamson PR et al.: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7, 813-818 (2006).
18. Pirmohamed M, Lin K, Chadwick D, Park BK: TNFa promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56, 890-896 (2001).
19. Romano A, De Santis A, Romito A et al.: Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann. Allergy Asthma Immunol. 80, 433-437 (1998).
20. Vitezica ZG, Milpied B, Lonjou C et al.: HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 22, 540-541 (2008).
21. O'Donohue J, Oien KA, Donaldson P et al.: Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47, 717-720 (2000).
22. Hautekeete ML, Horsmans Y, van Waeyenberge C et al.: HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117, 1181-1186 (1999).
23. Donaldson PT, Bhatnagar P, Graham J et al. Susceptibility to drug induced liver injury determined by HLA Class II genotype. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases. CA, USA. Hepatology 48(Suppl.), 345 (2008).
24. Daly A, Day C: Genetic association studies in drug-induced liver injury. Semin. Liver Dis. 29, 400-411 (2009).
25. Daly A, Donaldson P, Bhatnagar P et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41, 816-819 (2009).
26. Kindmark A, Jawaid A, Harbron CG et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195 (2008).
27. Pellicano R, Lomuto M, Ciavarella G et al.: Fixed drug eruptions with feprazone are linked to HLA-B22. J. Am. Acad. Dermatol. 36, 782-784 (1997).
28. Pellicano R, Ciavarella G, Lomuto M, Di Giorgio G: Genetic susceptibility to fxed drug eruption: evidence for a link with HLA-B22. J. Am. Acad. Dermatol. 30, 52-54 (1994).
29. Ozkaya-Bayazit E, Akar U: Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J. Am. Acad. Dermatol. 45, 712-717 (2001).
30. Lieberman JA, Yunis J, Egea E et al.: HLA-B38, DR4, DQw3 and clozapine induced agranulocytosis in Jewish patients with schizophrenia. Arch. Gen. Psychiatry 45, 945-948 (1990).
31. Diez RA: HLA-B27 and agranulocytosis by levamisole. Immunol. Today 11, 270 (1990).
32. Batchelor JR, Welsh KI, Tinoco RM et al.: Hydralazine-induced systemic lupus erythematosis: infuence of HLA-DR and sex on susceptibility. Lancet 1, 1107-1109 (1980).
33. Dalle Vedove C, Del Giglio M, Schena D et al.: Drug-induced lupus erythematosis. Arch. Dermatol. Res. 301, 99-105 (2009).
34. Kim SH, Choi JH, Lee KW et al.: The human leucocyte antigen DRB1*1302-DQb1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin induced urticaria. Clin. Exp. Allergy 35, 339-344 (2005).
35. Kim SH, Hur GY, Choi JH, Park HS: Pharmacogenetics of aspirin-intolerant asthma. Pharmacogenomics 9, 85-91 (2008).
36. Rodriguez-Perez M, Gonzalez-Dominguez J, Mataran L et al. Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate. J. Rheumatol. 21, 41-43 (1994).
37. Speerstra F, Reekers P, van de Putte LB, Vandenbroucke JP: HLA associations in aurothioglucose-and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis. Tissue Antigens 27, 35-40 (1985).
38. Quiralte J, Sanchez-Garcia F, Torres MJ et al.: Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-infammatory drugs. J. Allergy Clin. Immunol. 103, 685-689 (1999).
39. Garlepp MJ, Dawkins RL, Christiansen FT: HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. Br. Med. J. (Clin. Res. Ed.) 286, 338-340 (1983).
40. Pachoula-Papasteriades C, Boki K, Varla-Leftheriotic M et al.: HLA-A-B-and-DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA. Dis. Markers 4, 35-41 (1986).
41. Kano Y, Shiohara T: The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol. Allergy Clin. North Am. 29, 481-501 (2009).
42. Shiohara T, Inaoka M, Kano Y: Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesvirus and antiviral and antidrug immune responses. Allerg Int. 55, 1-8 (2006).
43. Eshki M, Allanore L, Musette P et al.: Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable organ failure. Arch. Dermatol. 145, 67-72 (2009).
44. Tohyama M, Hashimoto K, Yasukawa M et al.: Association of human herpesvirus 6 reactivation with the faring and severity of drug-induced hypersensitivity síndrome. Br. J. Dermatol. 157, 934-940 (2007).
45. Komura K, Hasegawa M, Hamaguchi Y et al.: Drug-induced hypersensitivity syndrome associated with human herpesvirus 6 and cytomegalovirus reactivation. J. Dermatol. 32, 976-981 (2005).
46. Sieishima M, Yamanaka S, Fujisawa T et al.: Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br. J. Dermatol. 255, 344-349 (2006).
47. Gupta A, Eggo MC, Uetrecht JP et al.: Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulphonamides. Clin. Pharmcol. Ther. 51, 56-57 (1992).
48. Aota N, Shiohara T: Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. Autoimmun. Rev. 8, 488-494 (2009).
49. Matzinger P: The danger model: a renewed sense of self. Science 296, 301-305 (2002).
50. Park BK, Naisbitt DJ, Gordon SF et al.: Metabolic activation in drug allergies. Toxicology 158, 11-23 (2001).
51. Pichler WJ, Beeler A, Keller M et al.: Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol. Int. 55, 17-25 (2006).
52. Shapiro LE, Knowles SR, Shear NH: Comparative safety of tetracycline, minocycline and doxycycline. Arch. Dermatol. 133, 1224-1230 (1997).
53. Teraki Y, Shibuya M, Izaki S: Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Clin. Exp. Dermatol. DOI: 10.1111/j.1365-2230.2009.03718.x (2009) (Epub ahead of print).
54. Bastuji-Garin, Rzany B, Stern RS et al.: Clinical classifcation of cases of toxic epidermal necrolysis. Arch. Dermatol. 129, 92-96 (1993).
55. Stern RS, Albengres E, Carlson J et al.: An international comparison of case defnitions of severe adverse cutaneous reactions to medicines. Drug Saf. 8, 69-77 (1993).
56. Bossi P, Roujeau JC, Bricaire F, Caumes E: Stevens-Johnson syndrome associated with abacavir therapy. Clin. Inf. Dis. 35, 902 (2002).
57. Pahk R, Azu MC, Taira BR, Sandoval S: Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodefency virus. Clin. Exp. Dermatol. 34, E775-E777 (2009).
58. Chung WH, Hung SL, Yang JY et al.: Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14, 1343-1350 (2008).
59. Verneuil L, Ratajczak P, Allabert C et al.: Endothelial cell apoptosis in severe drug-induced bullous eruptions. Br. J. Derm. 161, 1371-1375 (2009).
60. Abe R, Shimizu T, Shibaki A et al.: Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am. J. Pathol. 162, 1515-1520 (2003).
61. Nassif A, Benussan A, Dorethee G et al.: Drug specifc cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118, 728-733 (2002).
62. Phillips E, Mallal S: HLA and drug-induced toxicity: Curr. Opin. Mol. Ther. 11, 231-242 (2009).
63. Limdi N, Veenstra D: Expectations, validity and reality in pharmacogenetics. J. Clin. Epidemiol. DOI:10.1016/j. jclinepi.2009.09.006 (2009) (Epub ahead of print).
64. Hetherington S, McGuirk S, Powell G et al.: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603-1614 (2001).
65. Shapiro M, Ward KM, Stern JJ: A near fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read. 11, 222-226 (2001).
66. Symonds W, Cutrell A, Edwards M et al.: Risk factor analysis of hypersensitivity reactions to abacavir. Clin. Ther. 24, 565-573 (2001).
67. Peyriere H, Nicolas J, Siffert M et al.: Hypersensitivity related to abacavir in two members of a family. Ann. Pharmacother. 35, 1291-1292 (2001).
68. Hughes AR, Mosteller M, Bansal AT et al.: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203-211 (2004).
69. Hernandez J, Cutrell A, Benny T et al.: Diagnosis of abacavir hypersensitivity reactions among patients not receiving abacavir in two blinded studies. Antivir. Ther. 8, L88 (2003).
70. Dejesus E, Herrera G, Teoflo E et al.: Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral naive HIV infected adults. Clin. Infect. Dis. 39, 1038-1046 (2004).
71. Guilleck RM, Ribaudo H, Shikuma CM et al.: Three versus four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. J. Am. Med. Assoc. 296, 769-781 (2006).
72. Dart Trial Team: Twenty-four week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA) Trop. Med. Int. Health 13, 6-16 (2008).
73. Phillips EJ, Sullivan JR, Knowles SR, Shear NH: Utility of patch testing in patients with hypersensitivity reactions associated with abacavir. AIDS 16, 2223-2226 (2002).
74. Phillips EJ, Wong GA, Kaul R et al.: Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 19, 979-981 (2005).
75. Shear NH, Milpied B, Bruynzeel DP, Phillips EJ: A review of drug patch testing and implications for HIV clinicians. AIDS 22, 999-1007 (2008).
76. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
77. Saag M, Balu R, Phillips E et al.: High sensitivity of human leucocyte antigen-B*5701 as a marker for immunologically confrmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46, 1111-1118 (2008).
78. Rauch A, Nolan D, Martin A et al.: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Inf. Dis. 43, 99-102 (2006).
79. Zucman D, Truchis P, Majerhold C et al.: Prospective screening for human leucocyte antigen B*5701 avoids abacavir hypersensitivity in the ethnically mixed French HIV population. J. Acquir. Immune Defc. Syndr. 45, 1-3 (2007).
80. Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequencies of abacavir hypersensitivity reactions. Antiviral Ther. 11 (Suppl. 3), 14 (2006).
81. Trottier B, Thomas R, Nguyen VK, Machouf N: How effectively HLA screening can reduce the early discontinuation of abacavir in real life. Presented at: International AIDS Society Meeting. Sydney, Australia July 22-25 (2007) (Abstract MOPEB002).
82. Lalonde RG, Thomas R, Rachlis A et al.: Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Tissue Antigens 75(1), 12-18 (2009).
83. Waters LJ, Mandalia S, Gazzard B et al.: Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 21, 2533-2534 (2007).
84. Young B, Squires K, Patel P et al.: First large multicentre open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 22, 1673-1675 (2008).
85. + T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28, 822-832 (2008). (Pubitemid 351784513)
86. Almeida CA, Martin AM, Nolan D et al.: Cytokine profling in abacavir hypersensitivity patients. Antivir. Ther. 13, 281-288 (2008).
87. Martin AM, Almeida CA, Cameron P et al.: Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 21, 1233-1244 (2007).
88. Phillips E, Nolan D, Thorborn D et al.: Genetic factors predicting abacavir hypersensitivity and tolerance in HLA-B*5701 positive individuals. Eur. J. Dermatol. 18, 247 (2008).
89. Phillips E, Mallal S: Drug hypersensitivity in HIV. Curr. Opin. Allergy Clin. Immunol. 7, 324-330 (2007).
90. Shenton JM, Popovic M, Uetrecht JP: Nevirapine hypersensitivity. In: Drug Hypersensitivity. Pichler WJ (Ed.), Karger AG, Basel, Switzerland 115-128 (2007).
91. Likanonsakul S, Rattanatham T, Feangvad S et al.: HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res. Ther. 6, 22 (2009).
92. Liechty CA, Solberg P, Mwima G et al.: Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS 19, 993-994 (2005).
93. Knowles SR, Shapiro LE, Shear NH: Anticonvulsant hypersensitivity syndrome: Incidence, prevention and management. Drug Saf. 21, 489-501 (1999).
94. Sierra NM, Garcia B, Marco J et al.: Cross hypersensitivity syndrome between phenytoin and carbamazepine. Pharm. World Sci. 27, 170-174 (2005).
95. Alfrevic A, Mills T, Harrington P et al.: Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet. Genomics 16, 287-296 (2006).
96. David CD, Pirmohamed M, Kitteringham NR et al.: Kinetic parameters of lymphocyte microsomal epoxide hydrolase in carbamazepine hypersensitive patients. Assessment by radiometric HPLC. Biochem. Pharmacol. 50, 1361-1366 (1995).
97. Kaniwa N, Saito Y, Aihara M et al.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9, 1617-1622 (2008).
98. Ikeda H, Takahashi Y, Yamazaki E et al.: HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 51(2), 297-300 (2009).
99. Lonjou C, Thomas L, Borot N et al.: A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 6, 265-268 (2006).
100. Aberg J, Kaplan J, Libman H et al.: Primary care guidelines for the management of persons infected with human immunodefciency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 49, 651-681 (2009).
101. Hammer SM, Eron JJ Jr, Reiss P et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS Society-USA panel. J. Am. Med. Assoc. 300, 555-570 (2008).
102. Phillips E, Mallal S: Successful translation of pharmacogenetics into the clinic. The abacavir example. Mol. Diag. Ther. 13, 1-9 (2009).
103. Hammond E, Almeida CA, Mamotte C et al.: External quality assessment of HLA-B*5701 reporting and international multicentre survey. Antivir. Ther. 12, 1027-1032 (2007).
104. Martin AM, Nolan D, Mallal S: HLA-B*5701 typing by sequence-specifc amplifcation: validation and comparison with sequence-based typing. Tissue Antigens 65, 571-574 (2005).
105. Hammond E, Mamotte C, Nolan D et al.: HLA-B*5701 typing: evaluation of an allele-specifc polymerase chain melting assay. Tissue Antigens 70, 58-61 (2007).
106. Martin AM, Krueger R, Almeida CA et al.: A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet. Genomics 16, 353-357 (2006).
107. Columbo S, Rauch A, Rotger M et al.: The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 198, 864-867 (2008).
108. Trahtenberg E, Bhattacharya T, Ladner M et al.: The HLA-B/-C haplotype block contains major determinants for host control of HIV. Genes Immun. 10, 673-677 (2009).
109. Phillips EJ, Mallal SA: Chapter 20: HLA and drug reactions. In: The HLA Complex in Biology and Medicine a Resource Book. Narinder K Mehra (Ed.). Jaypee Brothers, New Delhi, India (2010).